AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31676660
Drug: Mutual Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutual Aid Group Therapy (active control)
Trial: 31676660
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (CRGT and Mutual Aid Group Therapy)
Trial: 26797106
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g and tramadol 1 mg/kg (group 1T)
Trial: 26797106
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g and tramadol 1.5 mg/kg (group 1.5T)
Trial: 15515192
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urokinase (UK) instillation (100,000 IU in 150 ml normal saline daily)
Trial: 15515192
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-tuberculous agents only)
Trial: 11584199
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with dissection of the lateral lymph nodes including autonomic nerves (D2) followed by oral administration of carmofur for one year
Trial: 8200466
Drug: Balloon catheter
RxNorm normalized name: Paclitaxel coated angioplasty balloon catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon catheter with extra-amniotic saline infusion (BCEAS)
Trial: 23743017
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium concentration 135 mmol/L
Trial: 23743017
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium concentration 145 mmol/L
Trial: 22059307
Drug: Weekly 75-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 75-minute play program throughout the school year
Trial: 18272271
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 40 mg/day for 4 days
Trial: 12488233
Drug: Oroenteral diets
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oroenteral diets (oral drinks or duodenal infusions of complex formula)
Trial: 6429872
Drug: Intravenous feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous feeding
Trial: 12488233
Drug: Elemental formula
RxNorm normalized name: Elemental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental formula (duodenal infusion)
Trial: 8650464
Drug: Clonidine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (mean = 0.5 mg/day)
Trial: 3158125
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg, long‐acting preparation)
Trial: 23293082
Drug: Dexamethasone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (40 mg/day for 4 days)
Trial: 30882644
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality immersive training with computerized cognitive therapy (experimental group)
Trial: 30882644
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive therapy (control group)
Trial: 24727841
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g at weeks 0 and 2)
Trial: 20571129
Drug: Low magnitude,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low magnitude, high frequency mechanical stimulation (active treatment)
Trial: 18612883
Drug: Bupropion (BUPRO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (BUPRO, 300 mg/day)
Trial: 7594332
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of 30 mg twice daily of lansoprazole
Trial: 7594332
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip infusion of 30 mg twice daily of lansoprazole
Trial: 7594332
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of 60 mg once daily of lansoprazole
Trial: 7594332
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection (30 mg twice daily) vs intravenous bolus injection (60 mg once daily)
Trial: 7594332
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection vs intravenous drip infusion
Trial: 2302074
Drug: Lactate (LA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate (LA) bath (Na, 138; K, 1.5; Ca, 1.75; Mg, 0.75; Cl, 109.5; AC, 17.5; and D,L‐lactate, 17.5 mmol/L)
Trial: 2302074
Drug: Acetate (AC)
DrugBank: Acetate (DB14511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate (AC) bath (35 mmol/L)
Trial: 27767328
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate and Vilanterol (FF/VI; 100 μg and 25 μg respectively)
Trial: 16925790
Drug: Apotransferrin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apotransferrin (dosage regimens not specified)
Trial: 11255425
Drug: Ipriflavone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone, 200 mg 3 times per day (n = 234)
Trial: 8373842
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptives (Group III)
Trial: 31856838
Drug: AZD8848 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8848 60 μg
Trial: 26160083
Drug: Single intra-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intra-operative injection of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Trial: 26160083
Drug: Intra-operative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative and two post-operative injections of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Trial: 17610807
Drug: Direct individual
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct individual therapy
Trial: 19107656
Drug: Indirect individual
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect individual therapy
Trial: 19107656
Drug: Direct group
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct group therapy
Trial: 17610807
Drug: Indirect group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect group therapy
Trial: 19107656
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy control group
Trial: 8982417
Drug: n-docosanol 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-docosanol 10% cream (early treatment)
Trial: 8982417
Drug: n-docosanol 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-docosanol 10% cream (late treatment)
Trial: 1607535
Drug: Heparin (intravenous)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin (intravenous)
Trial: 19588640
Drug: Topical AzA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical AzA 15% gel and oral doxycycline (100 mg), both twice daily for ≤ 12 weeks
Trial: 19588640
Drug: Topical AzA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical AzA 15% gel
Trial: 19588640
Drug: Both AzA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both AzA gel and vehicle
Trial: 14706014
Drug: estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estramustine phosphate (560 mg/day) plus LHRH agonist
Trial: 14706014
Drug: flutamide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flutamide (375 mg/day) plus LHRH agonist
Trial: 8311350
Drug: urapidil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil (0.4 mg.kg‐1)
Trial: 27060705
Drug: Multiple-micronutrient (MMN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-micronutrient (MMN) capsules
Trial: 27060705
Drug: Iron-folate (IFA)
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron-folate (IFA) capsules
Trial: 19695406
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg BID for 15 days
Trial: 3310670
Drug: 250‐mg disulfiram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250‐mg disulfiram
Trial: 3310670
Drug: 1‐mg disulfiram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg disulfiram
Trial: 27256812
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of digoxin (0.25 mg), furosemide (5 mg), metformin (500 mg), and rosuvastatin (10 mg)
Trial: 27256812
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of digoxin, furosemide, metformin, and rosuvastatin
Trial: 27256812
Drug: Increased doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased doses of metformin
Trial: 27256812
Drug: Increased doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased doses of furosemide
Trial: 25975013
Drug: Salt supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt supplements (1/8th teaspoon salt, 750 mg) mixed in formula feeds 1 day prior to sweat testing
Trial: 25975013
Drug: No salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No salt supplement (control group)
Trial: 16473462
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of local anesthetic
Trial: 14612001
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 to 1.5 mg/kg on day 1 and day 5 posttransplant
Trial: 14612001
Drug: Methylprednisolone intraoperatively
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone intraoperatively followed by Neoral monotherapy, with Cellcept for 2-4 months
Trial: 28708791
Drug: Laparoscopic total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic total mesometrial resection (L-TMMR)
Trial: 19589891
Drug: Aggressive disease
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive disease management (e.g., infliximab treatment)
Trial: 3618627
Drug: Crystalline fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalline fructose (60 g) supplementation
Trial: 29777278
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in platelet count of 20 × 10^9/L
Trial: 19020154
Drug: Intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketorolac 31.5 mg
Trial: 16417730
Drug: CRASH protocol
RxNorm normalized name: Rash Relief Antibacterial
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRASH protocol with 3 mg of cetrorelix and stimulation with recombinant human FSH starting on cycle day 2
Trial: 10532103
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy including immunotherapy with epithalamin 100 mg, neoadjuvant intraarterial polychemotherapy with 5-fluorouracil 2 g/m2 and cisplatin 100 mg/m2, concurrent radiotherapy, and 4-6 courses of adjuvant polychemotherapy
Trial: 4072875
Drug: Cibenzoline (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (130 mg twice daily and 160 mg twice daily)
Trial: 4072875
Drug: Quinidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (300 mg every 6 hours and 400 mg every 6 hours)
Trial: 20522535
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg thrice weekly after dialysis
Trial: 10551054
Drug: Litt's Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litt's Oral Surgery Confidence Questionnaire (OSCQ)
Trial: 1984229
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic therapy (amoxicillin)
Trial: 6954863
Drug: Multivitamin-trace mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin-trace mineral supplement
Trial: 30403366
Drug: Impella therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impella therapy
Trial: 20094958
Drug: Amitriptyline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (mean dosage 55 mg, range: 12.5-150 mg) taken at bedtime following a self-titration protocol.
Trial: 18242045
Drug: Contraception and
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraception and postmenopausal hormone replacement therapy
Trial: 18242045
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and other drugs (anti-BAFF, TACI-Fc)
Trial: 18242045
Drug: Anti-TNF molecules
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF molecules
Trial: 10452624
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine with three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Trial: 10452624
Drug: Separate injections
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injections (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine and three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Trial: 10452624
Drug: Separate injections
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injections
Trial: 8591095
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with additional group work
Trial: 8591095
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without group work
Trial: 8591095
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for mothers
Trial: 8591095
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for children
Trial: 2669345
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (saline wet‐to‐dry compressive dressing)
Trial: 31586420
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg no load
Trial: 29228792
Drug: Mixed herbal
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed herbal formulation (Silybum marianum, Urtica dioica, Boswellia serrata) for 90 days
Trial: 25446887
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous (IV) calcifediol (450μg)
Trial: 25446887
Drug: Oral modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral modified-release (MR) calcifediol (450 or 900μg)
Trial: 22836514
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g PL/day
Trial: 22836514
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g PL/day
Trial: 22836514
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g PL/day + 2 g PSt/day
Trial: 18316290
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention (4 two-hour weekly sessions)
Trial: 17080927
Drug: New candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New candidate therapy for neuropathic pain
Trial: 14597641
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg aliskiren
Trial: 14597641
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aliskiren
Trial: 14597641
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aliskiren
Trial: 9607383
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg losartan
Trial: 8828996
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg nightly for 7-10 nights
Trial: 30672194
Drug: Neurological routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological routine treatment and western medicine rehabilitation therapy (Control)
Trial: 18521538
Drug: Isosorbide-5-mononitrate (5-ISMN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (5-ISMN) 30 mg three times daily for 7 days
Trial: 10561255
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (IFNalpha2a) administered three times weekly at 18 x 10(6) IU
Trial: 10561255
Drug: Interleukin‐2 (IL‐2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin‐2 (IL‐2) administered as a continuous intravenous infusion for 5 days (18 x 10(6) IU/m(2)/d)
Trial: 10561255
Drug: Cross-over treatment
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-over treatment after failure of IL-2 or IFNalpha2a
Trial: 8547958
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose IL-2 (4.5 million IU/day, 3 times weekly for 6 months)
Trial: 8547958
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose IL-2
Trial: 29972904
Drug: 65 μm
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 μm glycine powder air-polishing (GPAP) therapy
Trial: 29972904
Drug: Ultrasonic scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaling plus polishing paste therapy (Control)
Trial: 21464041
Drug: Insulin >6.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin >6.10 μU/ml
Trial: 21464041
Drug: Insulin <2.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin <2.75 μU/ml
Trial: 21464041
Drug: Insulin 2.75-4.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 2.75-4.10 μU/ml
Trial: 21464041
Drug: Insulin >6.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin >6.10 μU/ml with viral load <4.39 log(10) copies/ml
Trial: 21464041
Drug: Higher insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher insulin levels
Trial: 380606
Drug: Alprenolol 200
RxNorm normalized name: alprenolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol 200 mg b.i.d.
Trial: 28095787
Drug: Additional functional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional functional training as part of the habitual daily routine during short term stays at nursing homes after discharge from hospital.
Trial: 25588095
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence skills training (MST)
Trial: 23449357
Drug: Mf (MMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mf (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 3 months)
Trial: 23449357
Drug: MFP (MMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 12 months with 6 monthly infusions of 60 mg m(‐2) of cisplatin)
Trial: 21150915
Drug: Tryptophan (TRP)
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan (TRP) augmentation
Trial: 18808413
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg biw
Trial: 17378197
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of indometacin entric-coater tablets